Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII ≥ 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360.NLR ≥ 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Andrea
A
Casadei Gardini
Unit of Biostatistics and Clinical Trials, IRST IRCCS, Meldola, Italy.
Emanuela
E
Scarpi
Department of Medical Oncology, Ospedale Generale Provinciale di Macerata ASUR Marche AV3, Macerata, Italy.|Department of Medical Oncology, University Hospital Cagliari, Cagliari, Italy.
Luca
L
Faloppi
Department of Medical Oncology, University Hospital Cagliari, Cagliari, Italy.
Mario
M
Scartozzi
Medical Oncology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy.
Nicola
N
Silvestris
Medical Oncology Department, University Campus Bio-Medico, Via Álvaro del Portillo, Rome, Italy.
Daniele
D
Santini
Infectious Diseases and Interventional Ultrasound Unit, D. Cotugno Hospital, Naples, Italy.
Giorgio
G
de Stefano
Biosciences Laboratory, IRST IRCCS, Meldola, Italy.
Giorgia
G
Marisi
Medical Oncology Unit, University Hospital, Parma, Italy.
Francesca V
FV
Negri
DPT Internal Medicine, Faenza Hospital, Faenza, AUSL Romagna, Forli, Italy.
Francesco Giuseppe
FG
Foschi
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Martina
M
Valgiusti
Department of General Surgery, Morgagni-Pierantoni Hospiatal, AUSL Romagna, Forli, Italy.|Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Giorgio
G
Ercolani
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Giovanni Luca
GL
Frassineti
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000276:immunology*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007249:Inflammation / Q000276:immunology; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D000077157:Sorafenib
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib
biomarker; hepatocellular carcinoma; inflammation; neutrophil-to-lymphocyte ratio; systemic immune-inflammation index